Sigrid Therapeutics has submitted its annual report for 2025. Net sales rose to 12.8 MSEK, the loss narrowed to 22.1 MSEK and the equity ratio strengthened to 78 per cent. During the year the company entered into an exclusive global licensing and research collaboration.
Net sales
+648% vs 2024
Loss
49% lower vs 2024
Equity ratio
+17 pp vs 2024
Commercialisation lifted revenue
Net sales amounted to SEK 12,840,559 (SEK 1,716,621), an increase of 648 per cent. The company describes it as a sharp increase and attributes it mainly to continued commercialisation, increased sales of the company's products and a gradual scaling up of operations.
Around 3.5 MSEK, corresponding to around 27 per cent of revenue, relates to sales to the company's subsidiary in the US. According to the company, the transactions have been carried out on market terms.
Lower costs and higher equity
Operating expenses decreased 23 per cent, to 35.3 MSEK (46.1 MSEK). Other external expenses fell to 23.3 MSEK (33.7 MSEK), while personnel costs amounted to 10.9 MSEK (10.8 MSEK). The result for the year was −22.1 MSEK (−43.1 MSEK), which means the loss narrowed by 49 per cent.
A new share issue during the year increased equity by 36.2 MSEK. At year-end, equity amounted to 35.6 MSEK and the equity ratio to 78 per cent – an improvement of 17 percentage points. Cash and bank decreased to 18.1 MSEK (22.0 MSEK) and the average number of employees was 6.5 (6.7).
| 2025 | 2024 | Change | |
|---|---|---|---|
| Net sales | 12.8 | 1.7 | +648% |
| Profit/loss for the year | −22.1 | −43.1 | +49% |
| Equity | 35.6 | 21.5 | +66% |
| Cash and bank | 18.1 | 22.0 | −18% |
| Equity ratio | 78% | 61% | +17 pp |
Licensing agreement to broaden SiPore® into oral health
During the year the company entered into an exclusive global licensing and research collaboration with a listed consumer health company. The counterparty has operations in around twenty countries and an established portfolio in oral health and functional foods, but is not named in the annual report.
According to the company, the agreement will expand the use of SiPore® in consumer-oriented oral health. The collaboration aims to broaden the technology's commercial applications and enable the development of new products in the oral care segment.
After the end of the financial year
The company states that during 2026 it completed a capital raise, which will support continued operations, accelerate development initiatives and strengthen its commercial position ahead of coming growth phases.
In February 2026 a new CEO took office with a mandate to lead the company into its next phase, focusing on commercial scaling and continued partner development. The auditor recommends that the general meeting adopt the income statement and balance sheet, and the annual general meeting was held on 5 June 2026.
The company has since reported for the first half of 2026, with more recent figures than those in the annual report. We summarised that report on 11 August 2026.
Source: Sigrid Therapeutics AB, annual report and auditor's report for the financial year 1 January–31 December 2025. Percentage changes are calculated on the amounts reported in the report.
